|
- IRMS - Nicolae Testemitanu SUMPh
- 1. COLECȚIA INSTITUȚIONALĂ
- MedEspera: International Medical Congress for Students and Young Doctors
- MedEspera 2020
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/12020
Title: | The contributions to the study of gout medication |
Authors: | Ermurache, Cristina |
Keywords: | gout;medication;uricodepressants;analgesics |
Issue Date: | 2020 |
Publisher: | MedEspera |
Citation: | ERMURACHE, Cristina. The contributions to the study of gout medication. In: MedEspera: the 8th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2020, p. 361-362. |
Abstract: | Introduction. Gout is a chronic condition caused by the disorder of uric acid metabolism,
which is manifested clinically, first of all, by acute relapsing arthritis and the formation of
subcutaneous gouty nodules (tofi), formed from accumulations of microcrystals of
monosodium urate monohydrate. In the Republic of Moldova, gout is determined in 2.5% of
the population with asymptomatic hyperuricemia, but the morbidity varies from 0.3 to 2.1%.
Aim of study. The elucidation of clinical features and contemporary principles of
pharmacotherapy and monitoring of gout medication.
Materials and methods. We investigated 74 patients with different clinical forms of gout that
were hospitalized during 2019 in the Rheumatology Unit of the Republican Clinical Hospital.
Results. The prevalence by age is found in men between 51-60 years old (37.8%) and among
women at 61-70 years old (4.1%). Gout is most often reported among men (93.2%), which is
related to alcohol and food abuse (meat, beef, tomatoes); traumatic events, hunger and stress.
According to the observation sheets, patients most frequently present a period of illness and/or
worsening of the health status in the last years: 33.8% - up to 5 years and 31% - 6-10 years.
There is a higher incidence of chronic tophi gout (56.8%) and idiopathic chronic gout (35.1%),
which makes us conclude that patients addressed after specialized medical help in the hospital
only in case of worsening health, other gout attacks. being monitored by the family doctor in
ambulatory conditions. For the treatment of acute gout attacks and for their prevention more
frequently is used uricodepressive treatment with: Alopurinol (95.9%), Colchicine (32.4%),
Canefron (47.3%), analgesic treatment with antipyretic analgesics (39.2%), nonsteroidal antiinflammatory
drugs (87.8%) and corticosteroids (16.2%). The average bed days spent by the
patients in the Rheumatology Unit is 8 days. According to the observation sheets, it was
established that during the winter-spring period, 58.11% of the total number of patients were
undergoing treatment in hospital, which can be caused by the worsening of the disease during
the cold period or by the oscillations of the temperature during spring.Conclusions. The results of study indicate a higher incidence of chronic tofacial gout (56.8%)
and idiopathic chronic gout (35.1%). Patients hospitalized with chronic tofacial and idiopathic
gout were predominantly on medication with uricodepressants (95.9%), antipyretic analgesics
(39.2%), nonsteroidal anti-inflammatory drugs (87.8%) and steroids (16.2%) to improve their
health. |
URI: | https://medespera.asr.md/wp-content/uploads/ABSTRACT-BOOK.pdf http://repository.usmf.md/handle/20.500.12710/12020 |
Appears in Collections: | MedEspera 2020
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|